0IV3 Stock Chart & Stats
$1.46
-$0.03(-1.71%)
At close: 4:00 PM EDT
$1.46
-$0.03(-1.71%)
Day’s Range― - ―
52-Week Range$1.04 - $2.00
Previous CloseN/A
Volume48.57K
Average Volume (3M)31.31K
Market Cap
$982.98M
Enterprise Value$807.52
Total Cash (Recent Filing)$300.85M
Total Debt (Recent Filing)$122.14M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume23,030
30 Day Avg. Volume31,312
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.33Price Target Upside196.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$236.28M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthRevenue growth and expanding prescriber coverage indicate RYTELO is gaining commercial traction. Continued adoption can improve operating leverage and provide a more durable base for funding Geron’s hematology pipeline, subject to reimbursement and persistence.
Operating LeverageOperating expenses fell about 4% in H1 while revenue rose 24%, showing early operating leverage. If this discipline persists as commercial scale grows, it can narrow losses and extend the company’s ability to invest in clinical development.
Clinical Pipeline SupportReal-world evidence consistent with Phase III results strengthens confidence in RYTELO’s clinical foundation. Supporting data for IMpactMF also improve the strategic value of the pipeline and could enable future growth if ongoing trials succeed.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not yet self-funding. Continued cash burn may require external financing or balance-sheet resources, creating dilution risk and limiting flexibility for commercial and clinical investment.
Ongoing Net LossesAlthough operating losses are narrowing, Geron remains materially unprofitable. Sustainable earnings depend on continued RYTELO growth, expense control and successful pipeline development; any slowdown could prolong losses and intensify financing pressure.
Clinical And Regulatory UncertaintyPotential changes to the interim analysis introduce uncertainty around trial readouts and the regulatory pathway for IMpactMF. This can affect development timing, capital allocation and the predictability of future indications beyond the current commercial product.
Geron News
0IV3 FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest share price was $1.04 and its highest was $2.00 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $982.98M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 16.045%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GB:0IV3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (196.80% Upside)
$4.33 (196.80% Upside)
Blogger Sentiment
Bullish
GB:0IV3 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
0IV3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all GB:0IV3 earnings summaries0IV3 Stock 12 Month Forecast
Average Price Target
$4.33
▲(196.80% Upside)